{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T07:18:37Z","timestamp":1794381517710,"version":"4.9.0"},"reference-count":124,"publisher":"American Chemical Society (ACS)","issue":"20","license":[{"start":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T00:00:00Z","timestamp":1790985600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001321","name":"National Research Foundation","doi-asserted-by":"publisher","award":["120419"],"award-info":[{"award-number":["120419"]}],"id":[{"id":"10.13039\/501100001321","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001321","name":"National Research Foundation","doi-asserted-by":"publisher","award":["137961"],"award-info":[{"award-number":["137961"]}],"id":[{"id":"10.13039\/501100001321","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001321","name":"National Research Foundation","doi-asserted-by":"publisher","award":["137979"],"award-info":[{"award-number":["137979"]}],"id":[{"id":"10.13039\/501100001321","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001321","name":"National Research Foundation","doi-asserted-by":"publisher","award":["145774"],"award-info":[{"award-number":["145774"]}],"id":[{"id":"10.13039\/501100001321","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001322","name":"South African Medical Research Council","doi-asserted-by":"publisher","award":["2021\/033"],"award-info":[{"award-number":["2021\/033"]}],"id":[{"id":"10.13039\/501100001322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cienti\u0301fico e Tecnolo\u0301gico","doi-asserted-by":"publisher","award":["304610\/2023-2"],"award-info":[{"award-number":["304610\/2023-2"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cienti\u0301fico e Tecnolo\u0301gico","doi-asserted-by":"publisher","award":["402141\/2023-7"],"award-info":[{"award-number":["402141\/2023-7"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cienti\u0301fico e Tecnolo\u0301gico","doi-asserted-by":"publisher","award":["440053\/2022-6"],"award-info":[{"award-number":["440053\/2022-6"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cienti\u0301fico e Tecnolo\u0301gico","doi-asserted-by":"publisher","award":["443533\/2024-5"],"award-info":[{"award-number":["443533\/2024-5"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The silent pandemic of antimicrobial resistance (AMR) continues to drive global morbidity and mortality. Resistance is often mediated by co-expression of serine \u03b2-lactamases (SBLs) and metallo-\u03b2-lactamases (MBLs), limiting treatment options. While several SBL inhibitors are clinically available, MBL inhibitors are yet to reach the market, and only a few candidates are in late-stage development. Dual-\u03b2-lactamase inhibitors remain an unmet goal. To preserve existing antibiotics, alternative strategies are required. This perspective highlights triple combination therapy comprising a \u03b2-lactam antibiotic, an SBL inhibitor, and an MBL-targeting agent to achieve broader coverage. Notably, in 2025, the U.S Food and Drug Administration (FDA) has approved aztreonam\u2212avibactam (Emblaveo), in combination with metronidazole, for adults with complicated intra-abdominal infections who have limited or no alternative treatment options. Expanding such strategies may help mitigate AMR and support ongoing antimicrobial development efforts.<\/jats:p>","DOI":"10.1021\/acs.jmedchem.6c00399","type":"journal-article","created":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T19:06:50Z","timestamp":1791486410000},"page":"23075-23091","source":"Crossref","is-referenced-by-count":3,"title":["Triple Combination Therapy: A Promising Path Forward against \u03b2-Lactamase-Mediated Resistance"],"prefix":"10.1021","volume":"69","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4428-2241","authenticated-orcid":true,"given":"Nakita","family":"Reddy","sequence":"first","affiliation":[{"name":"University of KwaZulu-Natal , , ,","place":["Durban, South Africa, 4001"]},{"name":"South African Medical Research Council , , ,","place":["Pretoria, South Africa, 0084"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2310-5107","authenticated-orcid":true,"given":"Jose\u0301 Roge\u0301rio A.","family":"Silva","sequence":"additional","affiliation":[{"name":"University of KwaZulu-Natal , , ,","place":["Durban, South Africa, 4001"]},{"name":"Federal University of Para\u0301 , , ,","place":["Bele\u0301m, Brazil, 66075-110"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9453-6812","authenticated-orcid":true,"given":"Per I.","family":"Arvidsson","sequence":"additional","affiliation":[{"name":"University of KwaZulu-Natal , , ,","place":["Durban, South Africa, 4001"]},{"name":"Karolinska Institutet , , ,","place":["Stockholm, Sweden, 17177"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0606-2053","authenticated-orcid":true,"given":"Hendrik G.","family":"Kruger","sequence":"additional","affiliation":[{"name":"University of KwaZulu-Natal , , ,","place":["Durban, South Africa, 4001"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2511-2503","authenticated-orcid":true,"given":"Thavendran","family":"Govender","sequence":"additional","affiliation":[{"name":"Ansynth Laboratories PTY LTD , 498 Grove End Drive , ,","place":["Durban, South Africa, 4068"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7134-6258","authenticated-orcid":true,"given":"Tricia","family":"Naicker","sequence":"additional","affiliation":[{"name":"University of KwaZulu-Natal , , ,","place":["Durban, South Africa, 4001"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2026,10,3]]},"reference":[{"key":"2026102305064716700_cit1","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s40290-025-00572-z","article-title":"Combating Antimicrobial Resistance: Role of Key Stakeholders with Focus on the Pharmaceutical Sector","volume":"39","author":"Sharma","year":"2025","journal-title":"Pharm. Med."},{"key":"2026102305064716700_cit2","unstructured":"World Health Organization.\n          \n          WHO Publishes List of Bacteria for Which New Antibiotics Are Urgently Needed, 2017; https:\/\/www.who.int\/news\/item\/27-02-2017-whopublishes-list-of-bacteria-for-which-new-antibiotics-are-urgentlyneeded (accessed 29 June 2023)."},{"key":"2026102305064716700_cit3","unstructured":"World Health Organization\n          . WHO Bacterial Priority Pathogens List, 2024: Bacterial Pathogens of Public Health Importance to Guide Research, Development and Strategies to Prevent and Control Antimicrobial Resistance, 2024. https:\/\/www.who.int\/publications\/i\/item\/9789240093461 (accessed 15 May 2026)."},{"issue":"2","key":"2026102305064716700_cit4","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1021\/jacsau.2c00532","article-title":"Chemical Basis of Combination Therapy to Combat Antibiotic Resistance","volume":"3","author":"Si","year":"2023","journal-title":"JACS Au"},{"key":"2026102305064716700_cit5","doi-asserted-by":"publisher","first-page":"107228","DOI":"10.1016\/j.bpc.2024.107228","article-title":"Metallo-\u03b2-lactamase inhibitors: A continuing challenge for combating antibiotic resistance","volume":"309","author":"Kang","year":"2024","journal-title":"Biophys. Chem."},{"issue":"3","key":"2026102305064716700_cit6","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1128\/aac.01009-09","article-title":"Updated Functional Classification of \u03b2-Lactamases","volume":"54","author":"Bush","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"issue":"8","key":"2026102305064716700_cit7","doi-asserted-by":"publisher","first-page":"3393","DOI":"10.1039\/D5MD00035A","article-title":"Navigating the complexities of drug development for metallo-\u03b2-lactamase inhibitors","volume":"16","author":"Reddy","year":"2025","journal-title":"RSC Med. Chem."},{"issue":"7","key":"2026102305064716700_cit8","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1080\/13543776.2020.1767070","article-title":"A 2018\u22122019 patent review of metallo beta-lactamase inhibitors","volume":"30","author":"Reddy","year":"2020","journal-title":"Expert Opin. Ther. Pat."},{"issue":"5815","key":"2026102305064716700_cit9","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/291489a0","article-title":"Monocyclic \u03b2-lactam antibiotics produced by bacteria","volume":"291","author":"Sykes","year":"1981","journal-title":"Nature"},{"issue":"1","key":"2026102305064716700_cit10","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1128\/aac.21.1.85","article-title":"Azthreonam (SQ 26,776), a synthetic monobactam specifically active against aerobic gram-negative bacteria","volume":"21","author":"Sykes","year":"1982","journal-title":"Antimicrob. Agents Chemother."},{"issue":"6","key":"2026102305064716700_cit11","doi-asserted-by":"publisher","first-page":"723","DOI":"10.3390\/antibiotics11060723","article-title":"Cefiderocol: Systematic Review of Mechanisms of Resistance, Heteroresistance and In Vivo Emergence of Resistance","volume":"11","author":"Karakonstantis","year":"2022","journal-title":"J. Antibiot."},{"issue":"5","key":"2026102305064716700_cit12","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01406-22","article-title":"Epidemiology of Resistance Determinants Identified in Meropenem-Nonsusceptible Enterobacterales Collected as Part of a Global Surveillance Study, 2018 to 2019","volume":"67","author":"Estabrook","year":"2023","journal-title":"Antimicrob. Agents Chemother."},{"issue":"11","key":"2026102305064716700_cit13","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1007\/s40121-024-01044-8","article-title":"Navigating the Current Treatment Landscape of Metallo-\u03b2-Lactamase-Producing Gram-Negative Infections: What are the Limitations?","volume":"13","author":"Grabein","year":"2024","journal-title":"Infect. Dis. Ther."},{"issue":"2","key":"2026102305064716700_cit14","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00991-23","article-title":"Relative inhibitory activities of the broad-spectrum \u03b2-lactamase inhibitor taniborbactam against metallo-\u03b2-lactamases","volume":"68","author":"Terrier","year":"2024","journal-title":"Antimicrob. Agents Chemother."},{"issue":"10","key":"2026102305064716700_cit15","doi-asserted-by":"publisher","first-page":"2779","DOI":"10.1093\/jac\/dkv166","article-title":"OP0595, a new diazabicyclooctane: mode of action as a serine \u03b2-lactamase inhibitor, antibiotic and \u03b2-lactam \u2018enhancer\u2019","volume":"70","author":"Morinaka","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"key":"2026102305064716700_cit16","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01484-18","article-title":"Single-Center Evaluation of the Pharmacokinetics of WCK 5222 (Cefepime- Zidebactam Combination) in Subjects with Renal Impairment","volume":"63","author":"Preston","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"issue":"4","key":"2026102305064716700_cit17","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1093\/jac\/dky522","article-title":"Activity of nacubactam (RG6080\/OP0595) combinations against MBL-producing Enterobacteriaceae","volume":"74","author":"Mushtaq","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"issue":"2","key":"2026102305064716700_cit18","doi-asserted-by":"publisher","first-page":"168","DOI":"10.3390\/pathogens14020168","article-title":"\u03b2-Lactam\/\u03b2-Lactamase Inhibitor Combination Antibiotics Under Development","volume":"14","author":"Katsarou","year":"2025","journal-title":"Pathog"},{"issue":"7","key":"2026102305064716700_cit19","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1056\/NEJMoa2304748","article-title":"Cefepime\u2212taniborbactam in complicated urinary tract infection","volume":"390","author":"Wagenlehner","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"2026102305064716700_cit20","doi-asserted-by":"publisher","first-page":"e01602","DOI":"10.1128\/aac.01602-23","article-title":"In vitro and in vivo activities of KSP-1007, a broad-spectrum inhibitor of serine- and metallo-beta-lactamases, in combination with meropenem against carbapenem-resistant Gram-negative bacteria","volume":"68","author":"Takemoto","year":"2024","journal-title":"Antimicrob. Agents Chemother."},{"key":"2026102305064716700_cit21","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00784-25","article-title":"Phase 1, randomized, double-blind, placebo-controlled, ascending single- and multiple-dose study of the safety, tolerability, and pharmacokinetics of intravenous xeruborbactam (QPX7728) in healthy adult subjects","volume":"69","author":"Herna\u0301ndez-Mitre Mp","year":"2025","journal-title":"Antimicrob. Agents Chemother."},{"key":"2026102305064716700_cit22","doi-asserted-by":"publisher","first-page":"1092556","DOI":"10.3389\/fmicb.2022.1092556","article-title":"\u03b2-Lactam potentiators to re-sensitize resistant pathogens: Discovery, development, clinical use and the way forward","volume":"13","author":"Narendrakumar","year":"2023","journal-title":"Front. Microbiol."},{"issue":"5","key":"2026102305064716700_cit23","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1128\/aac.11.5.852","article-title":"Clavulanic Acid: a Beta-Lactamase-Inhibiting Beta-Lactam from Streptomyces clavuligerus","volume":"11","author":"Reading","year":"1977","journal-title":"Antimicrob. Agents Chemother."},{"issue":"3","key":"2026102305064716700_cit24","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1128\/AAC.14.3.414","article-title":"CP-45,899, a beta-lactamase inhibitor that extends the antibacterial spectrum of \u03b2-lactams: Initial bacteriological characterization","volume":"14","author":"English","year":"1978","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1036","key":"2026102305064716700_cit25","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1098\/rstb.1980.0048","article-title":"Beta-lactamase inactivation by mechanism-based reagents","volume":"289","author":"Fisher","year":"1980","journal-title":"Philos. Trans. R. Soc. Lond. B Biol. Sci."},{"key":"2026102305064716700_cit26","doi-asserted-by":"publisher","first-page":"112829","DOI":"10.1016\/j.ejmech.2020.112829","article-title":"\u03b2-lactam antibiotics: An overview from a medicinal chemistry perspective","volume":"208","author":"Lima","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"2026102305064716700_cit27","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1111\/j.1469-0691.2007.01847.x","article-title":"Sulbactam-containing beta-lactamase inhibitor combinations","volume":"14","author":"Akova","year":"2008","journal-title":"Clin. Microbiol. Infect."},{"issue":"12","key":"2026102305064716700_cit28","doi-asserted-by":"publisher","first-page":"3832","DOI":"10.3390\/molecules27123832","article-title":"Recent Developments to Cope the Antibacterial Resistance via \u03b2-Lactamase Inhibition","volume":"27","author":"Iqbal","year":"2022","journal-title":"Molecules"},{"key":"2026102305064716700_cit29","doi-asserted-by":"publisher","first-page":"ciae403","DOI":"10.1093\/cid\/ciae403","article-title":"Infectious Diseases Society of America 2024 Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections","author":"Tamma","year":"2024","journal-title":"Clin. Infect. Dis."},{"issue":"6","key":"2026102305064716700_cit30","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1007\/s40265-024-02035-2","article-title":"Cefepime\/Enmetazobactam: First Approval","volume":"84","author":"Keam","year":"2024","journal-title":"Drugs"},{"issue":"3","key":"2026102305064716700_cit31","doi-asserted-by":"publisher","DOI":"10.1128\/mbio.01793-21","article-title":"Penicillanic Acid Sulfones Inactivate the Extended-Spectrum \u03b2-Lactamase CTX-M-15 through Formation of a Serine-Lysine Cross-Link: an Alternative Mechanism of \u03b2-Lactamase Inhibition","volume":"13","author":"Hinchliffe","year":"2022","journal-title":"mBio"},{"issue":"5","key":"2026102305064716700_cit32","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00105-19","article-title":"Beyond Piperacillin-Tazobactam: Cefepime and AAI101 as a Potent \u03b2-Lactam\u2212\u03b2-Lactamase Inhibitor Combination","volume":"63","author":"Papp-Wallace","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"issue":"4","key":"2026102305064716700_cit33","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1080\/17460913.2025.2468112","article-title":"Cefepime-enmetazobactam: first approved cefepime-\u03b2- lactamase inhibitor combination for multi-drug resistant Enterobacterales","volume":"20","author":"Bhowmick","year":"2025","journal-title":"Future Microbiol."},{"issue":"2","key":"2026102305064716700_cit34","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1093\/jac\/dkh358","article-title":"In vitro activity of AVE1330A, an innovative broad-spectrum non-\u03b2-lactam \u03b2-lactamase inhibitor","volume":"54","author":"Bonnefoy","year":"2004","journal-title":"J. Antimicrob. Chemother."},{"issue":"29","key":"2026102305064716700_cit35","doi-asserted-by":"publisher","first-page":"11663","DOI":"10.1073\/pnas.1205073109","article-title":"Avibactam is a covalent, reversible, non\u2212\u03b2-lactam \u03b2-lactamase inhibitor","volume":"109","author":"Ehmann","year":"2012","journal-title":"Proc. Natl. Acad. Sci."},{"key":"2026102305064716700_cit36","doi-asserted-by":"publisher","first-page":"1060736","DOI":"10.3389\/fgene.2022.1060736","article-title":"Biochemical exploration of \u03b2-lactamase inhibitors","volume":"13","author":"Arer","year":"2023","journal-title":"Front. Genet."},{"issue":"9","key":"2026102305064716700_cit37","doi-asserted-by":"publisher","first-page":"17104","DOI":"10.1038\/nmicrobiol.2017.104","article-title":"ETX2514 is a broad-spectrum \u03b2-lactamase inhibitor for the treatment of drug-resistant Gram-negative bacteria including Acinetobacter baumannii","volume":"2","author":"Durand-Re\u0301ville","year":"2017","journal-title":"Nat. Microbiol."},{"issue":"3","key":"2026102305064716700_cit38","doi-asserted-by":"publisher","first-page":"221","DOI":"10.3390\/antibiotics14030221","article-title":"A comprehensive overview of antibacterial agents for combating Multidrug-Resistant bacteria: the current landscape, development, future opportunities, and challenges","volume":"14","author":"Gajic","year":"2025","journal-title":"J. Antibiot."},{"issue":"4","key":"2026102305064716700_cit39","doi-asserted-by":"publisher","first-page":"307","DOI":"10.3390\/pathogens14040307","article-title":"New \u03b2-Lactam\/\u03b2-Lactamase Inhibitor Combination Antibiotics","volume":"14","author":"Sargianou","year":"2025","journal-title":"Pathogens"},{"issue":"9","key":"2026102305064716700_cit40","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1016\/S1473-3099(23)00184-6","article-title":"Efficacy and safety of sulbactam-durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii-calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK)","volume":"23","author":"Kaye","year":"2023","journal-title":"Lancet Infect. Dis."},{"issue":"12","key":"2026102305064716700_cit41","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01612-17","article-title":"Kinetics of Sulbactam Hydrolysis by \u03b2-Lactamases, and Kinetics of \u03b2-Lactamase Inhibition by Sulbactam","volume":"61","author":"Shapiro","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"issue":"3","key":"2026102305064716700_cit42","doi-asserted-by":"publisher","first-page":"dlaf096","DOI":"10.1093\/jacamr\/dlaf096","article-title":"Clinical efficacy, safety and pharmacokinetics of novel \u03b2-lactam\/\u03b2-lactamase inhibitor combinations: a systematic review","volume":"7","author":"Alarcia-Lacalle","year":"2025","journal-title":"JAC-Antimicrob. Resist."},{"issue":"4","key":"2026102305064716700_cit43","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/j.idc.2020.05.001","article-title":"Resistance to Novel \u03b2-Lactam-\u03b2-Lactamase Inhibitor Combinations: The Price of Progress","volume":"34","author":"Papp-Wallace","year":"2020","journal-title":"Infect. Dis. Clin. North Am."},{"issue":"4","key":"2026102305064716700_cit44","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1093\/cid\/ciac097","article-title":"Evolution of Imipenem-Relebactam Resistance Following Treatment of Multidrug-Resistant Pseudomonas aeruginosa Pneumonia","volume":"75","author":"Shields","year":"2022","journal-title":"Clin. Infect. Dis."},{"issue":"12","key":"2026102305064716700_cit45","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.3390\/antibiotics11121793","article-title":"Acinetobacter baumannii Resistance to Sulbactam\/Durlobactam: A Systematic Review","volume":"11","author":"Principe","year":"2022","journal-title":"J. Antibiot."},{"issue":"2","key":"2026102305064716700_cit46","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01935-19","article-title":"Biochemical Activity of Vaborbactam","volume":"64","author":"Tsivkovski","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"2026102305064716700_cit47","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01443-17","article-title":"Vaborbactam: Spectrum of Beta-Lactamase Inhibition and Impact of Resistance Mechanisms on Activity in Enterobacteriaceae","volume":"61","author":"Lomovskaya O","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"issue":"11","key":"2026102305064716700_cit48","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.3390\/antibiotics10111341","article-title":"Antimicrobial Activity of Aztreonam in Combination with Old and New \u03b2-Lactamase Inhibitors against MBL and ESBL Co-Producing Gram-Negative Clinical Isolates: Possible Options for the Treatment of Complicated Infections","volume":"10","author":"Morroni","year":"2021","journal-title":"J. Antibiot."},{"issue":"12","key":"2026102305064716700_cit49","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01224-17","article-title":"New Delhi Metallo-\u03b2-Lactamase 1 Catalyzes Avibactam and Aztreonam Hydrolysis","volume":"61","author":"Lohans","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"2026102305064716700_cit50","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.molliq.2019.03.006","article-title":"Insight into the catalytic hydrolysis mechanism of New Delhi metallo-\u03b2-lactamase to aztreonam by molecular modeling","volume":"282","author":"Yu","year":"2019","journal-title":"J. Mol. Liq."},{"issue":"1","key":"2026102305064716700_cit51","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1111\/febs.14695","article-title":"Crystal structures of VIM-1 complexes explain active site heterogeneity in VIM-class metallo-\u03b2-lactamases","volume":"286","author":"Salimraj","year":"2019","journal-title":"FEBS J."},{"issue":"10","key":"2026102305064716700_cit52","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1021\/bi501547k","article-title":"Structural basis of activity against aztreonam and extended-spectrum cephalosporins for two carbapenem-hydrolyzing class D \u03b2-lactamases from Acinetobacter baumannii","volume":"54","author":"Mitchell","year":"2015","journal-title":"Biochemistry"},{"issue":"13","key":"2026102305064716700_cit53","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1007\/s40265-021-01580-4","article-title":"Cefiderocol : A Review in Serious Gram-Negative Bacterial Infections","volume":"81","author":"Syed","year":"2021","journal-title":"Drugs"},{"issue":"9","key":"2026102305064716700_cit54","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.1093\/jac\/dkac221","article-title":"Evolution of \u03b2-lactamase-mediated cefiderocol resistance","volume":"77","author":"Fro\u0308hlich","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1","key":"2026102305064716700_cit55","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s13613-023-01153-6","article-title":"Rationale and evidence for the use of new beta-lactam\/beta-lactamase inhibitor combinations and cefiderocol in critically ill patients","volume":"13","author":"Barbier","year":"2023","journal-title":"Ann. Intensive Care"},{"issue":"8","key":"2026102305064716700_cit56","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1093\/jac\/dkad200","article-title":"In vitro activity of cefiderocol against MBL-producing Gram-negative bacteria collected in North America and Europe in five consecutive annual multinational SIDERO-WT surveillance studies (2014\u22122019)","volume":"78","author":"Takemura","year":"2023","journal-title":"J. Antimicrob. Chemother."},{"issue":"7","key":"2026102305064716700_cit57","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.3390\/antibiotics12071172","article-title":"In Vitro Activity of Cefiderocol against a Global Collection of Carbapenem-Resistant Acinetobacter baumannii Isolates","volume":"12","author":"Seifert","year":"2023","journal-title":"J. Antibiot."},{"issue":"2","key":"2026102305064716700_cit58","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/S1473-3099(20)30796-9","article-title":"Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial","volume":"21","author":"Bassetti","year":"2021","journal-title":"Lancet Infect. Dis."},{"issue":"4","key":"2026102305064716700_cit59","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.cmi.2021.11.025","article-title":"European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine)","volume":"28","author":"Paul","year":"2022","journal-title":"Clin. Microbiol. Infect."},{"issue":"1","key":"2026102305064716700_cit60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40560-022-00647-y","article-title":"Clinical effectiveness of tigecycline in combination therapy against nosocomial pneumonia caused by CR-GNB in intensive care units: a retrospective multi-centre observational study","volume":"11","author":"Yang","year":"2023","journal-title":"J. Intensive Care"},{"issue":"9","key":"2026102305064716700_cit61","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1093\/jac\/dkr242","article-title":"Efficacy and safety of tigecycline: a systematic review and meta-analysis","volume":"66","author":"Yahav","year":"2011","journal-title":"J. Antimicrob. Chemother."},{"issue":"12","key":"2026102305064716700_cit62","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1093\/cid\/cis270","article-title":"Excess deaths associated with tigecycline after approval based on noninferiority trials","volume":"54","author":"Prasad","year":"2012","journal-title":"Clin. Infect. Dis."},{"key":"2026102305064716700_cit63","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.jgar.2021.10.020","article-title":"A retrospective, multicentre evaluation of eravacycline utilisation in community and academic hospitals","volume":"29","author":"Hobbs","year":"2022","journal-title":"J. Glob. Antimicrob. Resist."},{"issue":"6","key":"2026102305064716700_cit64","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1093\/cid\/ciy1029","article-title":"IGNITE4: Results of a Phase 3, Randomized, Multicenter, Prospective Trial of Eravacycline vs Meropenem in the Treatment of Complicated Intraabdominal Infections","volume":"69","author":"Solomkin","year":"2018","journal-title":"Clin. Infect. Dis."},{"issue":"1","key":"2026102305064716700_cit65","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.ijantimicag.2018.09.013","article-title":"Resistance to fosfomycin: Mechanisms, Frequency and Clinical Consequences","volume":"53","author":"Falagas","year":"2019","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"8","key":"2026102305064716700_cit66","doi-asserted-by":"publisher","first-page":"500","DOI":"10.3390\/antibiotics9080500","article-title":"Fosfomycin as Partner Drug for Systemic Infection Management. A Systematic Review of Its Synergistic Properties from In Vitro and In Vivo Studies","volume":"9","author":"Antonello","year":"2020","journal-title":"J. Antibiot."},{"issue":"7\u22128","key":"2026102305064716700_cit67","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1080\/13543776.2023.2262763","article-title":"An updated patent review of metallo-\u03b2-lactamase inhibitors (2020\u22122023)","volume":"33","author":"Elsa Denakpo","year":"2023","journal-title":"Expert Opin. Ther. Pat."},{"issue":"11","key":"2026102305064716700_cit68","doi-asserted-by":"publisher","first-page":"10556","DOI":"10.1021\/acs.jmedchem.5c00553","article-title":"Harder than Metal: Challenging Antimicrobial Resistance with Metallo-\u03b2-lactamase Inhibitors","volume":"68","author":"De Falco","year":"2025","journal-title":"J. Med. Chem."},{"issue":"8","key":"2026102305064716700_cit69","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1038\/s41579-025-01169-8","article-title":"The global resistance problem and the clinical antibacterial pipeline","volume":"23","author":"Theuretzbacher","year":"2025","journal-title":"Nat. Rev. Microbiol."},{"issue":"6","key":"2026102305064716700_cit70","doi-asserted-by":"publisher","DOI":"10.1128\/aac.02415-19","article-title":"ZN148 Is a Modular Synthetic Metallo-Beta-Lactamase Inhibitor That Reverses Carbapenem Resistance in Gram-Negative Pathogens In Vivo","volume":"64","author":"Samuelsen","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"issue":"6","key":"2026102305064716700_cit71","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00203-21","article-title":"Novel Specific Metallo-Beta-Lactamase Inhibitor ANT2681 Restores Meropenem Activity to Clinically Effective Levels against NDM-Positive Enterobacterales","volume":"65","author":"Zalacain","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1","key":"2026102305064716700_cit72","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.jgar.2013.01.005","article-title":"Carbapenemases: Partners in crime","volume":"1","author":"Bush","year":"2013","journal-title":"J. Glob. Antimicrob. Resist."},{"issue":"3","key":"2026102305064716700_cit73","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01963-19","article-title":"VNRX-5133 (Taniborbactam), a Broad-Spectrum Inhibitor of Serine- and Metallo-\u03b2-Lactamases, Restores Activity of Cefepime in Enterobacterales and Pseudomonas aeruginosa","volume":"64","author":"Hamrick","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"issue":"18","key":"2026102305064716700_cit74","doi-asserted-by":"publisher","first-page":"8544","DOI":"10.1021\/acs.jmedchem.9b00911","article-title":"Bicyclic Boronate VNRX-5133 Inhibits Metallo- and Serine-\u03b2-Lactamases","volume":"62","author":"Krajnc","year":"2019","journal-title":"J. Med. Chem."},{"issue":"7","key":"2026102305064716700_cit75","doi-asserted-by":"publisher","first-page":"648","DOI":"10.3390\/antibiotics13070648","article-title":"New Agents Are Coming, and So Is the Resistance","volume":"13","author":"Keck","year":"2024","journal-title":"J. Antibiot."},{"issue":"6","key":"2026102305064716700_cit76","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00130-20","article-title":"Biochemical Characterization of QPX7728, a New Ultrabroad-Spectrum Beta-Lactamase Inhibitor of Serine and Metallo-Beta-Lactamases","volume":"64","author":"Tsivkovski","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"issue":"8","key":"2026102305064716700_cit77","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00757-20","article-title":"In Vitro Activity of the Ultrabroad-Spectrum-Beta-Lactamase Inhibitor QPX7728 against Carbapenem-Resistant Enterobacterales with Varying Intrinsic and Acquired Resistance Mechanisms","volume":"64","author":"Nelson","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"issue":"4","key":"2026102305064716700_cit78","doi-asserted-by":"publisher","first-page":"476","DOI":"10.3390\/ph15040476","article-title":"\u03b2-Lactam Antibiotics and \u03b2-Lactamase Enzymes Inhibitors, Part 2: Our Limited Resources","volume":"15","author":"Alfei","year":"2022","journal-title":"J. Pharm."},{"issue":"19","key":"2026102305064716700_cit79","doi-asserted-by":"publisher","first-page":"4217","DOI":"10.1021\/acs.biochem.5c00336","article-title":"Structural Insights into the Role of the Stereochemistry of the Cyclopropyl Ring in the Inhibitory Activity of Xeruborbactam against SME-1 Class A Carbapenemase","volume":"64","author":"Dhankhar","year":"2025","journal-title":"Biochemistry"},{"issue":"10","key":"2026102305064716700_cit80","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00879-22","article-title":"Intrinsic Antibacterial Activity of Xeruborbactam In Vitro: Assessing Spectrum and Mode of Action","volume":"66","author":"Sun","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"issue":"6","key":"2026102305064716700_cit81","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1093\/jac\/dkab067","article-title":"Activity of cefepime\/zidebactam (WCK 5222) against \u2018problem\u2019 antibiotic-resistant Gram-negative bacteria sent to a national reference laboratory","volume":"76","author":"Mushtaq","year":"2021","journal-title":"J. Antimicrob. Chemother."},{"issue":"6","key":"2026102305064716700_cit82","doi-asserted-by":"publisher","DOI":"10.1128\/aac.02529-16","article-title":"WCK 5107 (Zidebactam) and WCK 5153 Are Novel Inhibitors of PBP2 Showing Potent \u201cBeta-Lactam Enhancer\u201d Activity against Pseudomonas aeruginosa, Including Multidrug-Resistant Metallo-Beta-Lactamase-Producing High-Risk Clones","volume":"61","author":"Moya","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"issue":"4","key":"2026102305064716700_cit83","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1093\/jac\/dkad033","article-title":"Development of an optimized and practical pharmacokinetics\/pharmacodynamics analysis method for aztreonam\/nacubactam against carbapenemase-producing K. pneumoniae","volume":"78","author":"Igarashi","year":"2023","journal-title":"J. Antimicrob. Chemother."},{"issue":"6","key":"2026102305064716700_cit84","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1093\/jac\/dkaa036","article-title":"Effective inhibition of PBPs by cefepime and zidebactam in the presence of VIM-1 drives potent bactericidal activity against MBL-expressing Pseudomonas aeruginosa","volume":"75","author":"Moya","year":"2020","journal-title":"J. Antimicrob. Chemother."},{"issue":"1","key":"2026102305064716700_cit85","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s12941-023-00606-x","article-title":"Compassionate use of a novel \u03b2-lactam enhancer-based investigational antibiotic cefepime\/zidebactam (WCK 5222) for the treatment of extensively-drug-resistant NDM-expressing Pseudomonas aeruginosa infection in an intra-abdominal infection-induced sepsis patient: a case report","volume":"22","author":"Dubey","year":"2023","journal-title":"Ann. Clin. Microbiol. Antimicrob."},{"issue":"3","key":"2026102305064716700_cit86","doi-asserted-by":"publisher","first-page":"115327","DOI":"10.1016\/j.diagmicrobio.2021.115327","article-title":"In vitro activity of cefepime\/zidebactam (WCK 5222) against recent Gram-negative isolates collected from high resistance settings of Greek hospitals","volume":"100","author":"Bhagwat","year":"2021","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"2026102305064716700_cit87","unstructured":"AbbVie\n          . U.S. FDA approves EMBLAVEO\u2122 (aztreonam and avibactam) for the treatment of adults with complicated intra-abdominal infections with limited or no treatment options. 2025. https:\/\/news.abbvie.com\/2025-02-07-U-S-FDA-Approves-EMBLAVEO-TM-aztreonam-and-avibactam-for-the-Treatment-of-Adults-With-Complicated-Intra-Abdominal-Infections-With-Limited-or-No-Treatment-Options (accessed Sep 11, 2025)."},{"issue":"8","key":"2026102305064716700_cit88","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.3390\/antibiotics10081012","article-title":"The Revival of Aztreonam in Combination with Avibactam against Metallo-\u03b2-Lactamase-Producing Gram-Negatives: A Systematic Review of In Vitro Studies and Clinical Cases","volume":"10","author":"Mauri","year":"2021","journal-title":"Antibiotics"},{"issue":"1","key":"2026102305064716700_cit89","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s12866-021-02108-2","article-title":"Avibactam potentiated the activity of both ceftazidime and aztreonam against S. maltophilia clinical isolates in vitro","volume":"21","author":"Lin","year":"2021","journal-title":"BMC Microbiol."},{"issue":"2","key":"2026102305064716700_cit90","doi-asserted-by":"publisher","first-page":"dlad032","DOI":"10.1093\/jacamr\/dlad032","article-title":"Aztreonam\/avibactam activity against a large collection of carbapenem-resistant Enterobacterales (CRE) collected in hospitals from Europe, Asia and Latin America (2019\u221221)","volume":"5","author":"Sader","year":"2023","journal-title":"JAC-Antimicrob. Resist."},{"issue":"3","key":"2026102305064716700_cit91","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1093\/jac\/dkz497","article-title":"Pharmacokinetics and safety of aztreonam\/avibactam for the treatment of complicated intra-abdominal infections in hospitalized adults: results from the REJUVENATE study","volume":"75","author":"Cornely","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"issue":"6","key":"2026102305064716700_cit92","doi-asserted-by":"publisher","first-page":"2732","DOI":"10.1128\/aac.01768-09","article-title":"In Vitro Double and Triple Bactericidal Activities of Doripenem, Polymyxin B, and Rifampin against Multidrug-Resistant Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Escherichia coli","volume":"54","author":"Urban","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"issue":"11","key":"2026102305064716700_cit93","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1038\/s41579-022-00731-y","article-title":"Anti-tuberculosis treatment strategies and drug development: challenges and priorities","volume":"20","author":"Dartois","year":"2022","journal-title":"Nat. Rev. Microbiol."},{"issue":"6","key":"2026102305064716700_cit94","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e27984","article-title":"Unraveling resistance mechanisms in combination therapy: A comprehensive review of recent advances and future directions","volume":"10","author":"Morales-Dura\u0301n","year":"2024","journal-title":"Heliyon"},{"issue":"02","key":"2026102305064716700_cit95","doi-asserted-by":"publisher","first-page":"305","DOI":"10.3855\/jidc.14912","article-title":"Ceftazidime-avibactam plus metronidazole vs. meropenem in complicated intra-abdominal infections: Indian subset from RECLAIM","volume":"16","author":"Rodgers","year":"2022","journal-title":"J. Infect. Dev. Ctries."},{"issue":"4","key":"2026102305064716700_cit96","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1093\/jac\/dkx496","article-title":"Clinical outcomes after combination treatment with ceftazidime\/avibactam and aztreonam for NDM-1\/OXA-48\/CTX-M-15-producing Klebsiella pneumoniae infection","volume":"73","author":"Shaw","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"issue":"9","key":"2026102305064716700_cit97","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01008-17","article-title":"Ceftazidime-Avibactam and Aztreonam, an Interesting Strategy To Overcome Beta-Lactam Resistance Conferred by Metallo-Beta-Lactamases in Enterobacteriaceae and Pseudomonas aeruginosa","volume":"61","author":"Davido","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"issue":"5","key":"2026102305064716700_cit98","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1080\/14787210.2025.2473047","article-title":"Past, present, and future perspectives on aztreonam and avibactam","volume":"23","author":"Bush","year":"2025","journal-title":"Expert Rev. Anti. Infect. Ther."},{"issue":"8","key":"2026102305064716700_cit99","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1007\/s10096-024-04859-y","article-title":"Outcomes of 23 patients diagnosed with New Delhi metallo-beta-lactamase (NDM)-producing Klebsiella pneumoniae infection treated with ceftazidime\/avibactam and aztreonam at a single center in Poland","volume":"43","author":"Guzek","year":"2024","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"issue":"11","key":"2026102305064716700_cit100","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1093\/cid\/ciaa586","article-title":"Efficacy of Ceftazidime-avibactam Plus Aztreonam in Patients With Bloodstream Infections Caused by Metallo-\u03b2-lactamase\u2212Producing Enterobacterales","volume":"72","author":"Falcone","year":"2020","journal-title":"Clin. Infect. Dis."},{"issue":"4","key":"2026102305064716700_cit101","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1093\/cid\/ciz1155","article-title":"Monitoring Ceftazidime-Avibactam and Aztreonam Concentrations in the Treatment of a Bloodstream Infection Caused by a Multidrug-Resistant Enterobacter sp. Carrying Both Klebsiella pneumoniae Carbapenemase\u22124 and New Delhi Metallo-\u03b2-Lactamase\u22121","volume":"71","author":"Yasmin","year":"2019","journal-title":"Clin. Infect. Dis."},{"issue":"4","key":"2026102305064716700_cit102","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01507-23","article-title":"A multi-species outbreak of VIM-producing carbapenem-resistant bacteria in a burn unit and subsequent investigation of rapid development of cefiderocol resistance","volume":"68","author":"Freiberg","year":"2024","journal-title":"Antimicrob. Agents Chemother."},{"issue":"5","key":"2026102305064716700_cit103","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01474-23","article-title":"Difficult-to-treat (DTR) Pseudomonas aeruginosa harboring Verona-Integron metallo-beta-lactamase blaVIM: infection management and molecular analysis","volume":"68","author":"Vega","year":"2024","journal-title":"Antimicrob. Agents Chemother."},{"key":"2026102305064716700_cit104","doi-asserted-by":"publisher","DOI":"10.1016\/j.idcr.2024.e01946","article-title":"Novel case of combination antibiotic therapy for treatment of a complicated polymicrobial urinary tract infection with one organism harboring a metallo-\u03b2-lactamase (MBL) in a pregnant patient","volume":"36","author":"Ruddy","year":"2024","journal-title":"IDCases"},{"issue":"12","key":"2026102305064716700_cit105","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00936-22","article-title":"Pharmacokinetics of Ceftazidime-Avibactam in Combination with Aztreonam (COMBINE) in a Phase 1, Open-Label Study of Healthy Adults","volume":"66","author":"Lodise","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"issue":"4","key":"2026102305064716700_cit106","doi-asserted-by":"publisher","first-page":"ofae140","DOI":"10.1093\/ofid\/ofae140","article-title":"Clinical Outcomes for Patients With Monomicrobial vs Polymicrobial Acinetobacter baumannii-calcoaceticus Complex Infections Treated With Sulbactam-Durlobactam or Colistin: A Subset Analysis From a Phase 3 Clinical Trial","volume":"11","author":"McLeod","year":"2024","journal-title":"Open Forum Infect. Dis."},{"issue":"8","key":"2026102305064716700_cit107","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01063-24","article-title":"Acinetobacter baumannii treatment strategies: a review of therapeutic challenges and considerations","volume":"69","author":"Kubin","year":"2025","journal-title":"Antimicrob. Agents Chemother."},{"issue":"12","key":"2026102305064716700_cit108","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01426-19","article-title":"Exploring Aztreonam in Combination with Ceftazidime- Avibactam or Meropenem-Vaborbactam as Potential Treatments for Metallo- and Serine Beta-Lactamase-Producing Enterobacteriaceae","volume":"63","author":"Biagi","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"2026102305064716700_cit109","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.eng.2024.02.010","article-title":"The Triple Combination of Meropenem, Avibactam, and a Metallo-\u03b2-Lactamase Inhibitor Optimizes Antibacterial Coverage Against Different \u03b2-Lactamase Producers","volume":"38","author":"Ling","year":"2024","journal-title":"Engineering"},{"issue":"11","key":"2026102305064716700_cit110","doi-asserted-by":"publisher","first-page":"2653","DOI":"10.3390\/microorganisms11112653","article-title":"Taxifolin as a Metallo-\u03b2-Lactamase Inhibitor in Combination with Augmentin against Verona Imipenemase 2 Expressing Pseudomonas aeruginosa","volume":"11","author":"Benin","year":"2023","journal-title":"Microorganisms"},{"issue":"2","key":"2026102305064716700_cit111","doi-asserted-by":"publisher","first-page":"185","DOI":"10.3390\/pharmaceutics16020185","article-title":"Potentiation of Antibiotic Activity of Aztreonam against Metallo-\u03b2-Lactamase-Producing Multidrug-Resistant Pseudomonas aeruginosa by 3-O-Substituted Difluoroquercetin Derivatives","volume":"16","author":"Lee","year":"2024","journal-title":"Pharmaceutics"},{"issue":"9","key":"2026102305064716700_cit112","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00272-24","article-title":"Efficacy of aspergillomarasmine A\/meropenem combinations with and without avibactam against bacterial strains producing multiple \u03b2-lactamases","volume":"68","author":"Rotondo","year":"2024","journal-title":"Antimicrob. Agents Chemother."},{"key":"2026102305064716700_cit113","doi-asserted-by":"publisher","first-page":"fnac122","DOI":"10.1093\/femsle\/fnac122","article-title":"The in vitro and in vivo potential of metal-chelating agents as metallo-beta-lactamase inhibitors against carbapenem-resistant Enterobacterales","volume":"370","author":"Omolabi","year":"2022","journal-title":"FEMS Microbiol. Lett."},{"issue":"2","key":"2026102305064716700_cit114","doi-asserted-by":"publisher","first-page":"100918","DOI":"10.1016\/j.jbc.2021.100918","article-title":"Aspergillomarasmine A inhibits metallo-\u03b2-lactamases by selectively sequestering Zn2+","volume":"297","author":"Sychantha","year":"2021","journal-title":"J. Biol. Chem."},{"key":"2026102305064716700_cit115","unstructured":"Rongved, P.; Klem, B.\n          Combination therapy for bacterial infections comprising zinc-chelator, beta-lactam antibiotic and serine beta-lactamase inhibitor, WO 2024231524 A1, 2024."},{"issue":"13","key":"2026102305064716700_cit116","doi-asserted-by":"publisher","first-page":"7957","DOI":"10.1021\/acs.chemrev.1c00138","article-title":"Metallo-\u03b2-lactamases in the Age of Multidrug Resistance: From Structure and Mechanism to Evolution, Dissemination, and Inhibitor Design","volume":"121","author":"Bahr","year":"2021","journal-title":"Chem. Rev."},{"key":"2026102305064716700_cit117","doi-asserted-by":"publisher","first-page":"849006","DOI":"10.3389\/fphar.2022.849006","article-title":"Prediction of synergistic antibiotic combinations by graph learning","volume":"13","author":"Lv","year":"2022","journal-title":"Front. Pharmacol."},{"key":"2026102305064716700_cit118","doi-asserted-by":"publisher","first-page":"3477","DOI":"10.1021\/acs.jmedchem.5c03511","article-title":"Benchmarking Large Language Models for Drug Combination Alerts: Achieving Expert-Level Reliability via Knowledge Grounding and Contextual Reasoning","volume":"69","author":"Hu","year":"2026","journal-title":"J. Med. Chem."},{"issue":"1","key":"2026102305064716700_cit119","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s11686-023-00765-z","article-title":"Antimalarial drug combination predictions using the machine learning synergy predictor (MLSyPred\u00a9) tool","volume":"69","author":"Roche-Lima","year":"2024","journal-title":"Acta Parasitol."},{"issue":"10","key":"2026102305064716700_cit120","doi-asserted-by":"publisher","first-page":"3977","DOI":"10.1021\/acs.jcim.3c02015","article-title":"Machine learning models identify inhibitors of New Delhi metallo-\u03b2-lactamase","volume":"64","author":"Cheng","year":"2024","journal-title":"J. Chem. Inf. Model."},{"issue":"5","key":"2026102305064716700_cit121","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1111\/cbdd.13708","article-title":"Applications of machine-learning methods for the discovery of NDM-1 inhibitors","volume":"96","author":"Shi","year":"2020","journal-title":"Chem. Biol. Drug Des."},{"key":"2026102305064716700_cit122","unstructured":"World Health Organization\n          . WHO Releases Report on State of Development of Antibacterials, 2024. https:\/\/www.who.int\/news\/item\/14-06-2024-who-releases-report-on-state-of-development-of-antibacterials (accessed 22 September 2025)."},{"issue":"2","key":"2026102305064716700_cit123","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01168-23","article-title":"Structural basis of metallo-\u03b2-lactamase resistance to taniborbactam","volume":"68","author":"Drusin","year":"2024","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1","key":"2026102305064716700_cit124","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1093\/jac\/dkae367","article-title":"Resistance profiles of carbapenemase-producing Enterobacterales in a large centre in England: are we already losing cefiderocol?","volume":"80","author":"Baltas","year":"2024","journal-title":"J. Antimicrob. Chemother."}],"container-title":["Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.jmedchem.6c00399","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article-pdf\/69\/20\/23075\/68740000\/jm6c00399.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article-pdf\/69\/20\/23075\/68740000\/jm6c00399.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T09:11:09Z","timestamp":1792746669000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article\/69\/20\/23075\/5444240\/Triple-Combination-Therapy-A-Promising-Path"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,3]]},"references-count":124,"journal-issue":{"issue":"20","published-online":{"date-parts":[[2026,10,3]]},"published-print":{"date-parts":[[2026,10,22]]}},"URL":"https:\/\/doi.org\/10.1021\/acs.jmedchem.6c00399","relation":{},"ISSN":["0022-2623","1520-4804"],"issn-type":[{"value":"0022-2623","type":"print"},{"value":"1520-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,3]]}}}